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Background: 22q11.2 deletion syndrome (22q11.2DS) is the most common micro-deletion syndrome. The associated
22q11.2 deletion conveys the strongest known molecular risk for schizophrenia. Neurodevelopmental phenotypes,
including intellectual disability, are also prominent though variable in severity. Other developmental features include
congenital cardiac and craniofacial anomalies. Whereas existing mouse models have been helpful in determining the
role of some genes overlapped by the hemizygous 22q11.2 deletion in phenotypic expression, much remains unknown.
Simple model organisms remain largely unexploited in exploring these genotype-phenotype relationships.
Methods: We first developed a comprehensive map of the human 22q11.2 deletion region, delineating gene content,
and brain expression. To identify putative orthologs, standard methods were used to interrogate the proteomes of the
zebrafish (D. rerio), fruit fly (D. melanogaster), and worm (C. elegans), in addition to the mouse. Spatial locations of conserved
homologues were mapped to examine syntenic relationships. We systematically cataloged available knockout and
knockdown models of all conserved genes across these organisms, including a comprehensive review of associated
phenotypes.
Results: There are 90 genes overlapped by the typical 2.5 Mb deletion 22q11.2 region. Of the 46 protein-coding genes,
41 (89.1 %) have documented expression in the human brain. Identified homologues in the zebrafish (n = 37, 80.4 %)
were comparable to those in the mouse (n = 40, 86.9 %) and included some conserved gene cluster structures. There
were 22 (47.8 %) putative homologues in the fruit fly and 17 (37.0 %) in the worm involving multiple chromosomes.
Individual gene knockdown mutants were available for the simple model organisms, but not for mouse. Although
phenotypic data were relatively limited for knockout and knockdown models of the 17 genes conserved across all
species, there was some evidence for roles in neurodevelopmental phenotypes, including four of the six mitochondrial
genes in the 22q11.2 deletion region.
Conclusions: Simple model organisms represent a powerful but underutilized means of investigating the molecular
mechanisms underlying the elevated risk for neurodevelopmental disorders in 22q11.2DS. This comparative multi-species
study provides novel resources and support for the potential utility of non-mouse models in expression studies and
high-throughput drug screening. The approach has implications for other recurrent copy number variations associated
with neurodevelopmental phenotypes.
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22q11.2 deletion syndrome (22q11.2DS, MIM #188400/
#192430) is the most common micro-deletion syndrome
in humans with an estimated prevalence of at least 1 in
4000 live births [1, 2]. Formerly known as velocardiofa-
cial or DiGeorge syndrome, this multi-system condition
is associated with a broad range of developmental fea-
tures including congenital cardiac and palatal anomalies,
intellectual disabilities, hypoparathyroidism, and subtle
facial dysmorphism [2–4]. Developmental delay and later
onset disorders affecting the nervous system are particu-
larly common [5]. These include attention deficit hyper-
activity disorder [6, 7], anxiety disorders [8, 9], autism
[10, 11], epilepsy, schizophrenia [2, 12], and early-onset
Parkinson’s disease [13, 14]. The phenotypic manifestations
of the syndrome are thought to be related at least in part
to reduced gene dosage in the 22q11.2 deletion region that
in turn interferes with normal protein functioning [15].
The typical associated ~2.5 Mb 22q11.2 deletion is
present in >85 % of individuals with 22q11.2DS [16, 17],
while a smaller proximal nested ~1.5 Mb deletion occurs
in ~10 % of cases [18, 19]. The associated 22q11.2 dele-
tions are mediated by segmental duplications, or low-copy
repeats (LCRs) that confer susceptibility of the region to
copy number variation through non-allelic homologous
recombination [20, 21]. The penetrance and variable ex-
pressivity of major associated phenotypes appear to be
largely independent of deletion size [22, 23]. The few
mRNA sequencing and protein expression studies of indi-
viduals with 22q11.2DS published to date [24–33] illus-
trate the complexity of linking specific genes to the
phenotypes associated with this disorder. Much remains
to be known about the individual and collective roles of
22q11.2 deletion region genes in modulating associated
phenotypes. Model animals will undoubtedly play an es-
sential role in this discovery process.
Mouse models have already been proven useful for
characterizing the molecular function of 22q11.2 genes and
establishing a link between certain genes and 22q11.2DS
associated phenotypes [34]. The syntenic region on mouse
chromosome 16 has a high degree of gene conservation to
the human 22q11.2 region. Current engineered mouse
models include deletions of large portions of the syntenic
region and mutations of individual genes [34, 35]. How-
ever, simple model organisms could also prove to be
powerful tools for investigating genomic disorders such as
22q11.2DS. Their ease of genetic manipulation, amenability
to high-throughput behavioural screening, and short gen-
eration times make simple organisms attractive potential
resources. The potential for simple model organisms to re-
veal the genetic mechanisms underlying 22q11.2DS pheno-
types remains essentially unexamined however.
As an initial step in determining the utility of simple
model organisms in the study of 22q11.2DS, we generatedan updated, comprehensive 22q11.2DS human gene map
and investigated the evolutionary conservation status of
genes within the 22q11.2 region in three common model
organisms: the zebrafish, Danio rerio (D. rerio), the fruit
fly, Drosophila melanogaster (D. melanogaster), and the
worm, Caenorhabditis elegans (C. elegans). We included
the otherwise well-reviewed mouse models [34, 35] for
comparison. We then conducted a comprehensive review
of gene function and phenotypic alterations related to
22q11.2 gene homologue disruptions and developed a
novel comprehensive resource of available knockout and
knockdown models. The results may help to accelerate
the identification of novel genotype-phenotype correla-
tions in 22q11.2DS and inform pathogenesis of, and drug
development for this disorder and its commonly associ-
ated features.
Methods
Human 22q11.2 region characterization
The human 22q11.2DS deletion region, genetic content, and
order were mapped from NCBI Gene Homo sapiens Anno-
tation Release 105 using Affymetrix CytoScan HD (Santa
Clara, CA, USA) array mean breakpoints (chr22:18,820,
303–21, 489,474) ascertained from 16 patients with con-
firmed 22q11.2 deletions (Fig. 1). Fourteen of the 16 pa-
tients had deletions covering most of the 22q11.2 region
(~2.5 Mb) while two had smaller, nested proximal deletions.
The same region was obtained with a larger, previously
described patient population (n = 99) using Affymetrix Hu-
man SNP 6.0 breakpoints [3, 36]. All patients provided con-
sent and the study was approved by local research ethics
boards [3]. We accessed the Database of Genomic Variants
to establish the corresponding locations of major UCSC
segmental duplications across the deletion region (http://
dgv.tcag.ca/dgv/app/home; accessed 1 December 2014).
Build GRCh37 gene coordinates were used to ensure con-
gruency across all databases used in this study. We omitted
the few genes that move outside the 22q11.2 deletion re-
gion in build GRCh38 (i.e., the segment flanked by protein-
coding genes TMEM191B…RIMBP3).
To identify changes in gene expression conferred by
22q11.2 hemizygosity, a systematic literature review (current
to 1 December 2014) was conducted using PubMed to iden-
tify experimentally validated changes in 22q11.2 region gene
expression (mRNA) in patients with 22q11.2DS. The follow-
ing search terms were used: “22q11.2 deletion syndrome”,
“22q11.2DS”, “DiGeorge syndrome”, “velo-cardio-facial syn-
drome”, “velocardiofacial syndrome”, “VCFS”, “CATCH22”,
and “Shprintzen syndrome”, in conjunction with the name
of each gene (and all associated gene aliases from
GenBank). The Human Brain Transcriptome (http://hbatla
s.org/) was used to identify genes expressed in the brain
(mRNA signal ≥6) across the lifespan in any brain region
[37]. For genes (n = 10) not found in the Human Brain
Fig. 1 (See legend on next page.)
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Fig. 1 Genetic landscape of the human 22q11.2 region. The typical ~2.5-Mb 22q11.2DS deletion spans 90 RefSeq genes (see text for details). Region
breakpoints are mediated by four chromosome specific low-copy repeats (LCRA-D; approximate locations shown). Gene expression, indicated by a
green circled check mark, was established using The Human Brain Transcriptome. Data for decreased expression with hemizygosity were collated from
experimentally demonstrated [24, 28–33] reductions in gene expression in blood cells from patients with 22q11.2DS. Gene names within a rectangle
denote the 17 genes conserved across the mouse, zebrafish, fruit fly, and worm
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and associated gene expression databases (ArrayExpress,
Bgee and CleanEx) were consulted.
Gene conservation and function in model species
To identify putative orthologs of human 22q11.2 region
protein-coding genes in the zebrafish (D. rerio), fruit
fly (D. melanogaster), worm (C. elegans), and mouse
(M. musculus), we employed the reciprocal best hits
method, i.e., the protein products of genes in two different
genomes represent the best hit in the opposite genome,
using protein Basic Local Alignment Search Tool (blastp)
analysis with the UniProtKB database (http://www.unipro-
t.org/uni prot/) including both Swiss-Prot and TrEMBL en-
tries (accessed 1 December 2014). We ran blastp using
each of the 46 22q11.2 deletion region protein-coding genes
as a query against all proteins annotated in each genome of
interest, using default settings and a maximum E-value
threshold of 1 × 10−6 [38, 39]. We also required coverage of
at least 50 % of any of the protein sequences in the align-
ments. In instances of multiple protein isoforms due to al-
ternative splicing, the “canonical” sequence, as identified by
UniProtKB, was selected for blastp analysis. To find ortho-
logs as reciprocal best hits, we sorted blastp hits from the
highest to the lowest bit score. Using this sorting method,
the first hit was therefore the best hit. If the next hit had
the very same score, there would be more than one hit (the
method can therefore produce multiple orthologs). The
same procedure was performed in the opposite direction.
In the zebrafish, an organism that has undergone genome-
wide duplication, we included multiple hits if the scores of
putative homologues were very similar, and both hits were
consistently identified across multiple databases (e.g., RefSeq).
NCBI Entrez Gene was then used to individually search
all putative orthologs to establish organism-specific gene
location (Additional file 1). The conservation status of the
seven 22q11.2 region miRNAs identified was examined
using miRBase21 (accessed in December 2014) [40]. Hu-
man non-coding genes (n = 10) including one read-
through transcript, and pseudogenes (n = 27) in the
22q11.2 deletion region were not investigated further.
To identify available knockout and knockdown models
of the identified 22q11.2 region homologues and collate
their phenotypic manifestations, we conducted a systematic
search (accessed 1 December 2014) of species-specific data-
bases including: WormBase (http://www.wormbase.org/),
FlyBase (http://flybase.org/), ZFin (http://zfin.org/), andMGI (http://www.informatics.jax.org/) databases for C. ele-
gans, D. melanogaster, D. rerio, and M. musculus, respect-
ively. A secondary PubMed literature review confirmed
that all studies examining orthologs in our model organ-
isms of interest were included. Knockouts (homozygote)
were defined as mutant models that did not produce a
functional protein product due to a premature stop codon,
a disruptive insertion, or full excision of a gene. For all
model organisms discussed, we note only the availability
of homozygous knockouts; these are more difficult to gen-
erate and are required for heterozygous knockout animals
(the result of a cross of a homozygous knockout with a
wild-type strain). We have however provided the known
phenotypes of heterozygous knockout models for genes
conserved across all examined organisms. Knockdown
models were defined as those with reduced gene expres-
sion induced by any technology that interfered with the
translation of a gene after it had been transcribed. The 17
genes conserved across model organisms were examined
to document the availability of phenotypic information of
mutant models. Single gene mutations have been reported
in humans for 22q11.2DS genes, however these were out-
side the scope of this study.
Results
Characterization of the human 22q11.2 deletion region
The typical human 22q11.2 deletion overlapped 90 genes,
and the smaller proximal ~1.5 Mb deletion encompassed
55 of these genes (Fig. 1). Just over half (n = 46, 51.1 %) of
these 90 genes are protein-coding and of these, most
(n = 41, 89.1 %) are expressed in the human brain. For the
proximal nested deletion, there were 30 protein-coding
genes, 27 (90.0 %) of which are expressed in the brain. We
identified seven studies documenting gene expression in
22q11.2DS patients. These collectively demonstrated de-
creased expression of 32 (69.6 %) 22q11.2 region protein-
coding genes [24, 28–33] in blood cells from patients with
22q11.2DS relative to non-deleted controls (Fig. 1). Three
genes (TBX1, RTN4R, and P2RX6P) are not expressed in
blood, [24] and the remaining 11 (23.9 %) remain to be
studied in this context.
In the typical 22q11.2 region, there were also 27 pseudo-
genes, one read-through transcript (classified as a non-
coding RNA) (SEPT5…GP1BB), nine non-coding RNA
genes, and seven microRNAs (miRNAs; Fig. 1). Recent
studies propose that the miRNA processing protein Pasha,
encoded by DGCR8, which lies within the 22q11.2 deletion
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sion of target genes that contribute to the neuropsychiatric
phenotypes associated with 22q11.2DS, together with the
region’s high density of miRNAs [36, 41–43]. Three of the
seven miRNAs (MIR185, MIR1306, MIR1286) have been
found to be expressed in the brain, while two were not
(MIR3618, MIR649), [44] and the other two (MIR4761,
MIR6816) have yet to be investigated.22q11.2 region gene conservation in model organisms
The well-studied mouse syntenic region of the human
proximal (1.5 Mb) deletion located on chromosome 16
(MMU 16qA13; Fig. 2) contained 27 of the 30 human
protein-coding genes localized to the human proximal dele-
tion region (Fig. 1), the exceptions being clathrin, heavy
chain-like 1 (CLTCL1), chromosome 22 open reading frame
29 (C22orf29), and DiGeorge syndrome critical region-6-
like (DGCR6L). With respect to the typical 2.5 Mb deletion,Fig. 2 Comparative gene map of the human 22q11.2 region homologues. Prot
the reciprocal best hits method was used to compare protein sequences to ide
musculus), 40 conserved genes; zebrafish (D. rerio), 37 conserved genes; fruit fly (
genes. Locations of human genes and putative homologues were mapped usin
lines otherwise join homologues between species. See text for details40 of the 46 protein-coding genes are conserved in the
mouse (Fig. 2).
The zebrafish also exhibited a high degree of gene
conservation to the human 22q11.2DS region. In total,
37 (80.4 %) of the 46 protein-coding human homologues
had putative homologues in the zebrafish (Table 1,
Fig. 2). Compared to the genes contained in the human
22q11.2 region, the fruit fly had available homologues
for 22 (47.8 %) protein-coding genes, and the worm had
17 (37.0 %) available homologues.
Seventeen genes were conserved across all three of the
simple model species (Table 1) and in mice. By human pos-
ition, these are as follows: PRODH, DGCR14, SLC25A1,
HIRA,MRPL40,UFD1L,CDC45,TBX1,TXNRD2,TANGO2,
DGCR8,TRMT2A,MED15, PI4KA, SNAP29, AIFM3, SLC7A4
(Fig. 2). Notably, 16 (94.1 %) of these are expressed in the
human brain (Fig. 1), five of which encode mitochondrial
proteins (PRODH, SLC25A1,MRPL40,TXNRD2,TANGO2).
In the zebrafish, there were five genes (PRODH, SLC25A1,ein Basic Local Alignment Search Tool (blastp) analysis on UniProtKB using
ntify homologues of the 46 human protein-coding genes in the mouse (M.
D. melanogaster), 22 conserved genes and worm (C. elegans), 17 conserved
g NCBI Gene. Horizontal bars indicate clusters of two or more genes; fine
Table 1 Conservation status and available knockout (KO)/knockdown (KD) models of 22q11.2 deletion region protein-coding genes
Human protein-
coding genea
C. elegans D. melanogaster D. rerio M. musculus
Homologue
(n = 17)
% Modelb Homologue
(n = 22)
% Modelb Homologue
(n = 37)
% Modelb Homologue
(n = 40)
% Modelb
DGCR6 gdl 37 KO dgcr6 65 − Dgcr6 92 −
PRODH CELE_B0513.5 46 KD slgA 46 KO, KD LOC100537991 69 − Prodh 82 KO
prodha 63 KO
DGCR2 dgcr2 64 KO Dgcr2 93 KO
DGCR14 ess-2 30 KO, KD Es2 35 KD dgcr14 67 − Dgcr14 93 KO
TSSK2 Tssk2 92 KO
GSC2 LOC101885810 52 − Gsc2 76 KO
SLC25A1 K11H3.3 65 KD sea 67 KO, KD slc25a1a 78 KD Slc25a1 94 KO
slc25a1b 84 −
HIRA K10D2.1 33 KO, KD Hira 60 KO, KD hira 78 KD Hira 96 KO
MRPL40 mrpl-40 30 KD mRpL40 40 KO, KD mrpl40 50 − Mrpl40 75 KO
C22orf39 CG15908 32 KO, KD si:ch211..51 h9.6 49 − 2510002D24Rik 72 KO
UFD1L ufd-1 41 KD Ufd1-like 56 KO, KD ufd1l 87 KO Ufd1l 99 KO
CDC45 evl-18 29 KO, KD CDC45L 39 KO, KD cdc45 74 KO Cdc45 92 KO
CLDN5 cldn5a 57 KO, KD Cldn5 92 KO
cldn5b 54 −
SEPT5 sept5a 84 − Sept5 99 KO
sept5b 85 −
GP1BB gp1bb 46 − Gp1bb 90 KO
TBX1 mls-1 53 KO, KD org-1 58 KO, KD tbx1 72 KO, KD Tbx1 91 KO
GNB1L CG13192 30 KO, KD gnb1l 53 − Gnb1l 82 KO
TXNRD2 trxr-2 49 KO, KD Trxr-2 55 KD si:ch1073-179p4.3 71 − Txnrd2 86 KO
COMT comta 53 − Comt 80 KO
comtb 54 −
ARVCF arvcfb 64 KO Arvcf 92 KO
TANGO2 R186.1 29 KD Tango2 30 KO, KD tango2 64 − Tango2 88 −
DGCR8 pash-1 25 KO, KD pasha 37 KO, KD dgcr8 72 KO Dgcr8 95 KO
TRMT2A H24K24.4 27 KD CG3808 37 KO, KD trmt2a 56 KO Trmt2a 83 KO
RANBP1 ranbp1 73 KO Ranbp1 93 KO
ZDHHC8 zdhhc8b 57 KO Zdhhc8 92 KO
LOC388849 Gm7873 72 −
RTN4R rtn4r 45 KD Rtn4r 89 KO
SCARF2 scarf2 52 − Scarf2 82 KO
KLHL22 CG1812 30 KO, KD klhl22 60 − Klhl22 95 −
MED15 mdt-15c 26 KO, KD MED15 32 KO, KD med15b 60 KD Med15 90 −
PI4KA CELE_Y75B8A.24 38 KO, KD PI4KIIIalpha 45 KO, KD pi4kaa 84 KD Pi4ka 98 KO
SERPIND1 serpind1 54 − Serpind1 82 KO
SNAP29 snap-29 28 KO, KD Snap29 32 KO, KD snap29 51 KD Snap29 83 KO
CRKL crkl 82 KD Crkl 97 KO
AIFM3 F20D6.11 34 KD CG4199 38 KO, KD LOC100150876 66 − Aifm3 96 −
LZTR1 CG3711 51 KO, KD lztr1 81 − Lztr1 95 KO
THAP7 thap7 42 KO Thap7 93 −
Guna et al. Journal of Neurodevelopmental Disorders  (2015) 7:18 Page 6 of 16
Table 1 Conservation status and available knockout (KO)/knockdown (KD) models of 22q11.2 deletion region protein-coding genes
(Continued)
P2RX6 P2rx6 86 KO
SLC7A4 C50D2.2 43 KD CG13248 43 KO, KD slc7a4 64 KO Slc7a4 84 −
LRRC74B si:ch211-173a9.8 41 − Lrrc74b 68 −
aGenes ordered by proximal to distal 22q11.2 locus position. Genes CLTCL1, C22orf29, DGCR6L, USP41, LOC101927859, and ZNF74 have no putative homologues,
and are therefore not shown
bKnockout indicates a homozygous knockout model (heterozygous knockout models can be generated by crossing a homozygous knockout with a wild-type strain)
cIncluded due to confirmed functional homology [98], although did not meet minimal protein sequence coverage requirement at 50 %
Italicized genes have putative homologues across all four model organisms (n = 17). Blank cells indicate no identified homologue; − indicates no
knockout (KO) or knockdown (KD) model available. Percent (%) indicates sequence similarity to human protein. Homologues were identified using
blastp using the UniProtKB database. KO and KD models were identified from WormBase (http://www.wormbase.org/), FlyBase (http://flybase.org/),
ZFin (http://zfin.org/), and MGI (http://www.informatics.jax.org/) for C. elegans, D. melanogaster, D. rerio, and M. musculus, respectively. Data are
current to 2 December 2014
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logues were identified, likely due to gene locus duplication
[45] (Table 1; Fig. 2).
Certain genes maintained positional proximity across
species (Fig. 2; Additional file 1), indicating some con-
served synteny [46] (e.g., with minimal shuffling of order,
from human TBX1 to ZDHHC8, with an intact core
from HIRA to GNB1L, to mouse Tbx1 to Zdhhc8, and to
zebrafish tbx1 to tango2; Fig. 2). 22q11.2 region gene ho-
mologues were dispersed across 8 of the 25 zebrafish
chromosome pairs, with the largest clusters involving
chromosomes 5 and 8. 22q11.2 region homologues are
distributed across all five fruit fly chromosomes, and all
five autosomal worm chromosome pairs (Fig. 2).
No miRNAs were conserved in the zebrafish, fruit fly, or
worm. The two miRNA conserved in the mouse were
MIR185 and MIR1306. Human non-coding genes (n = 9),
a read-through transcript, and pseudogenes (n = 27) in
the 22q11.2 deletion region were not investigated in the
model organisms studied.
Availability of knockout and knockdown models of
22q11.2 region homologues in model organisms
The high proportion of conserved protein-coding genes
and their arrangement in the mouse has permitted the
construction of contiguous multi-gene deletion models.
These include several short and long deletion models, as
previously reviewed [34, 35]. Of the 40 homologous
genes in the mouse, 31 (77.5 %) had available homozy-
gous knockouts (Table 1). Notably, no mouse knock-
down models were identified.
In zebrafish, of the 32 protein-coding conserved genes
that did not have multiple putative homologues (i.e., exclud-
ing PRODH, SLC25A1, CLDN5, SEPT5, and COMT), ten
(31.3 %) genes had knockouts and six (18.8 %) had knock-
downs; one (3.1 %; TBX1) had both available (Table 1). Nei-
ther knockouts nor knockdowns were available for a
substantial proportion (n = 15, 46.9 %) of these 32 genes. In
the fruit fly, of the 22 protein-coding conserved genes, the
majority (n = 19, 86.4 %) had both knockout and knock-
down models available, two had only a knockout (9.1 %),and one had only a knockdown (4.5 %). In the worm, of
the 17 protein-coding conserved genes, nearly half (n = 8,
47.0 %) had knockdowns available, and nine (53.0 %) had
both knockdowns and knockouts (Table 2).
Availability of phenotypic information for conserved
22q11.2 region genes in animal models
Examination of the 17 genes conserved across species
showed substantial variability in the availability and com-
prehensiveness of phenotypic information for homozygous and
heterozygous knockouts, and knockdown models (Table 2). In
the mouse, there were 13 genes with mutants available, of
which nine had some form of phenotypic characterization.
Zebrafish also appeared to be under-investigated; of 12 con-
served genes with mutants available, phenotypic informa-
tion was available for only six. Notably, a DGCR8 knockout
has not been phenotypically assessed in zebrafish. More
phenotypic information was available for mutants in the
fruit fly (13 of 17 genes) and worm (15 genes), possibly due
to the use of forward genetic screens in these organisms
[47, 48]. Only six genes were phenotypically characterized
across all three of the simple model species (SLC25A1,
UFD1L, TBX1, MED15, PI4KA, and SNAP29). Findings
from these phenotypic studies are discussed below in the
context of clinical manifestations of 22q11.2DS. We note
that, as for all genetic studies, it is important to determine
whether phenotypic effects are related to a specific back-
ground strain. This is an important consideration for all
model animals including the mouse [49], zebrafish [50],
fruit fly [51], and worm [52]. For example, Prodh homozy-
gous in mice mutants were shown to be defective in pre-
pulse inhibition [53], but this effect was dependent on
genetic background [54].
Discussion
Here, we defined a comprehensive gene map of the most
common human micro-deletion syndrome, 22q11.2DS,
and conducted the first systematic examination of 22q11.2
deletion region gene conservation in simple model organ-
isms. We developed a comprehensive resource of available
knockout and knockdown models of conserved 22q11.2
Table 2 Phenotype of available knockout/knockdown models for highly conserved 22q11.2 deletion region genes (n = 17)
Lethality (Knockout models)a Knockout and knockdown phenotypes
Geneb C. elegans D.
melanogaster
D. rerio M.
musculus
C. elegans D. melanogaster D. rerio M. musculus
PRODH − No (KO) Not assessed
(KO, prodha); −
(LOC100537991)
No (KO) Reduced accumulation rate of
newly synthesized proteins,
extended life span, increased
thermo-tolerance (KD)
Hyperprolinemia, locomotor
defects including indecisive
movement patterns and
hypoactivity (KO); Not assessed
(KD)
Not assessed (KO, prodha); −
(LOC100537991)
Reduced male body weight and
prepulse inhibition (genetic
background dependent), impaired
fear conditioning, regionally altered
levels of proline (hyperprolinemia),
glutamate, gamma-aminobutyric
acid, and aspartate in the brain (KO)
DGCR14 Embryonic
lethality
(KO); No
(het-KO)
− − Not
assessed
(KO)
Higher frequency of male
progeny, meiotic prophase
defect (KD); Deregulated mRNA
processing (KO); Normal
phenotype (het-KO)
Not assessed (KD) − Not assessed (KO)
SLC25A1 − Embryonic
lethality (KO)
− (slc25a1a,
slc25a1b)
Majority
die before
12 weeks
post-natal
(KO)
Normal when assessed for
lethality, sterility, anatomical
morphology, development, and
growth (KD)
Chromosomal breaks and global
loss of DNA acetylation (KO)
Mitochondrial depletion, flattened
head, small heart, brain, inner ear,
intestine, and mandibular arch
skeleton with defect severity
proportional to gene suppression,
neuromuscular junction defects
regardless of phenotype severity
(KD, slc25a1a); Not assessed
(slc25a1b)
Mice examined at two weeks are
small and sickly, and show
generalized hypoplasia, most
severely in liver and bone
marrow (KO)
HIRA Embryonic
lethality
(KO)
Embryonic
lethality (KO)
− Embryonic
lethality
(KO); No
(het-KO)
Not assessed (KO, KD) Enhanced transcriptional
suppression through variegation
with transposable element
probe, offspring of null mothers
crossed with wild-type males do
not develop while paternal null
offspring show only partial le-
thality implying maternal effect
(KO); Not assessed (KD)
Not assessed (KD) Disrupted gastrulation, abnormal
cardiac development (e.g., heart
chambers), abnormal embryonic
tissue morphology, abnormal
placenta, craniofacial abnormalities,
failure of brain to fuse and
abnormal neural plate morphology
(KO); Decreased leukocyte cell
count (het-KO)
MRPL40 − Embryonic
lethality (KO)
− Not
assessed
(KO)
Slow growth, larval arrest,
reduced brood size, sterile
progeny (KD)
Gross neuroanatomical defects
due to under-proliferation of
neuroblast cells during neuro-
genesis (KO); Not assessed (KD)
− Not assessed (KO)
UFD1L − No (KO) Embryonic
lethality (KO)
Not
assessed
(KO); No
(het-KO)
Slow growth, gonad development
deficits, enlarged gut granules,
locomotor defect with deviations
in self-propelled movement,
patchy coloration, reduced life
span (KD)
Stress response reduced as
determined by virus infection
assay (KO); Not assessed (KD)
Decreased eye size, abnormal
head shape due to hypoplasia
and misarranged features,
necrotic central nervous system,
increased thickness of
mandibular arch skeleton,
hypoplastic gut and liver (KO)
Not assessed (KO); Viable with no
obvious heart defects (het-KO)
CDC45 Embryonic
lethality
(KO)
Lethal in the
larval stage
(KO)
Not assessed
(KO)
Embryonic
lethality
(KO); No
(het-KO)
Everted vulva, reduced brood
size, sterility associated with no
sperm development (KO); Sister
chromatid segregation defective
in early embryo, reduced brood
size (KD)
Gross neuroanatomy defective
due to reduced cellular
proliferation causing small
neuroblast size in the
developing brain (KO); Not
assessed (KD)
Not assessed (KO) Impaired proliferation of inner cell
mass after embryo implantation
(KO); Normal when assessed for
size, behaviour, and sterility
(het-KO)
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Table 2 Phenotype of available knockout/knockdown models for highly conserved 22q11.2 deletion region genes (n = 17) (Continued)
Lethality (Knockout models) Knockout and knockdown phenotypes
Genea C. elegans D.
melanogaster
D. rerio M.
musculus
C. elegans D. melanogaster D. rerio M. musculus
TBX1 No (KO) Partial
embryonic
lethality (KO)
Embryonic
lethality (KO)
Embryonic
lethality
(KO); No
(het-KO)
Abnormal uterine cell fate due to
transcriptional abnormalities (KO);
Normal when assessed for
sterility, anatomical morphology,
and development (KD)
Severely malformed or absent
adult muscle precursors and
supportive alary heart muscles
(KO); Not assessed (KD)
Severely abnormal cardiac
development (e.g., absent aortic
arch), severe pouch defects and
abnormal facial skeletal
development, abnormal inner
ear morphology (KO); Severely
abnormal cardiac development
(e.g., absent aortic arches) and
thymus (KD)
Severely abnormal cardiac
development (e.g., aortic arch),
abnormal inner, middle, and
outer ear morphology, abnormal
lymphangiogenesis, abnormal
cranial base morphology (KO);
Mild cardiac abnormalities (e.g.,
fourth aortic arch arteries) and
decreased prepulse inhibition
(het-KO)
TXNRD2 – – – Embryonic
lethality
(KO)
Hypersensitive to protein
aggregation induced paralysis
(KD) but otherwise normal when
assessed for morphology and
development (KO, KD)
Not assessed (KD) – Severe anemia and growth
retardation due to perturbed
cardiac development and
augmented apoptosis of
hematopoietic cells (KO)
TANGO2 – Not assessed
(KO)
Not assessed
(KO)
– Not assessed (KD) Not assessed (KO, KD) – –
DGCR8 No (KO) Lethal
before end
of pupal
stage (KO)
Not assessed
(KO)
Embryonic
lethality
(KO); No
(het-KO)
Accumulation of miRNA target
protein, decreased lifespan (KO);
Reduced miRNA processing,
accumulation of target mRNA,
vulva defects, enhanced
locomotor deficits of unc
mutant (uncoordinated)
phenotypes (KD)
Abnormal olfactory projection and
mushroom body neuron
morphology and neurophysiology
(KO); Not assessed (KD)
Not assessed (KO) Reduced dendritic spine
number, reduced dendritic
complexity, decreased prepulse
inhibition and abnormal spatial
working memory (het-KO)
TRMT2A No (KD) No (KO) Not assessed
(KO)
Not
assessed
(KO)
Not maternally sterile but
otherwise not assessed (KD)
Not sterile (KO); Not assessed
(KD)
Not assessed (KO) Not assessed (KO)
MED15 Reduced
lifespan
(KO)
Pupal
lethality (KO)
– – Sterile, small, increased apoptosis,
decreased protein expression,
changes in mRNA expression,
intestinal morphology, reduced
lifespan, uncoordinated
locomotion (KD); Hypersensitivity
to toxin exposure (KO, KD)
Abnormal wing development
(KO, het-KO); Abnormal wing
development and shortened
legs, formation of ectopic
sensory organs and induced
cellular apoptosis (KD)
Disruption of dorsal/ventral
patterning and mesoderm
development (KD)
–
PI4KA Embryonic
lethality
(KO)
Lethal
before end
of larval
stage (KO)
– Embryonic
lethality
(KO)
Slow growth and sterility (KD) Abnormal eye morphology,
neuromuscular junction
overgrowth (KO); Not assessed
(KD)
Decreased eye, head, and
mesenchymal cell proliferation,
increased apoptosis and necrosis
of brain cells (KD)
Premature death due to
degeneration of mucosal cells in
the stomach and intestines (KO)
SNAP29 Embryonic
lethality
(KO)
Pupal
lethality (KO)
– Pre-
weaning
lethality
(KO)
Defects in secretion from intestinal
epithelial cells (KO); Sterility
associated with endomitotic
oocytes and pre-mitotic maturation
of the oocyte, abnormal localization
of phospholipid membrane
components (KD)
Not assessed (KO); Synaptic
defects characterized by abnormal
basal neurotransmission. Lethality
observed in the pupal stage (KD)
Disrupted pigmentation,
epidermal irregular spatial
pattern, disorganized
keratinocyte cell surface (KD)
Not assessed (KO)
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Table 2 Phenotype of available knockout/knockdown models for highly conserved 22q11.2 deletion region genes (n = 17) (Continued)
AIFM3 – No (KO) – – Normal when assessed for
lifespan and sterility, anatomical
morphology, development, and
growth (KD)
Not sterile (KO); Not assessed
(KD)
– –
SLC7A4 – Not assessed
(KO)
Not assessed
(KO)
– Normal when assessed for
sterility and anatomical
morphology (KD)
Not assessed (KO, KD) Not assessed (KO) –
aKnockout (KO) indicates homozygous KO model phenotype; except where indicated as a heterozygous KO (het-KO) phenotype
bGenes ordered by proximal to distal 22q11.2 locus position; “–” indicates no knockout (KO) or knockdown (KD) model available. Lethality for KD models is not included as this may vary based on when the gene
is suppressed
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man 22q11.2 region protein-coding genes, a substantial
proportion is conserved in simple model organisms. These
mutant model organisms are amenable to extensive pheno-
typic characterization. This novel comparative multi-species
resource can be used to provide initial insights into how
simple animal models could be used to investigate the
multi-system congenital and neurodevelopmental condi-
tions associated with hemizygous 22q11.2 deletions.Advantages of using a non-murine animal model in the
study of 22q11.2DS
The amenability of the zebrafish, fruit fly, and worm to
genetic manipulation compared with the mouse could
facilitate rapid and cost-effective generation of individual
targeted gene and multi-gene mutations (Table 1). Such
manipulations will be essential to functional studies and
gene variant interpretation of 22q11.2 region genes.
Moreover, the ease of genetic manipulation could rapidly
improve our understanding of how the 22q11.2 deletion
may interact with the rest of the genome to mediate the
variable expressivity of 22q11.2DS associated phenotypes
through mechanisms such as translational modifications
due to the loss of one copy of DGCR8 and 22q11.2 re-
gion miRNA genes [55]. The relatively high proportion
of 22q11.2 deletion region gene knockouts available in
the mouse compared with the zebrafish and the worm is
notable given that the process of developing knockout
mouse models is expensive and time-consuming, calcu-
lated to take on average of about 1 year at a cost of more
than US $12,000 [56]. With the advent of the CRISPR/
Cas9 system, the cost and speed of developing knock-
outs for all organisms will substantially decrease [57].
Unlike the mouse, knockdown models for 22q11.2DS
homologues are available for the zebrafish, fruit fly, and
worm (Table 1). Gene knockdown technologies are advan-
tageous because they can be used to reduce gene expression
in a dose-dependent manner with a high degree of specifi-
city [58, 59], essential for examining 22q11.2DS, where
dose-dependency is thought to underlie phenotypic changes
[15]. All knockdowns found for 22q11.2 homologues in the
zebrafish were generated using morpholinos [60]. Knock-
downs in the worm and fruit fly commonly employed RNA
interference (RNAi) methods. Notably, it is possible to
knockdown two genes simultaneously using combinatorial
RNAi in C. elegans and D. melanogaster [61, 62]. There
are, as yet, no examples of this for 22q11.2 region
genes, although such experiments could yield critical
insights into the possibility of epistatic effects between
22q11.2 region genes that may mediate the complex ex-
pression of 22q11.2DS associated phenotypes [54]. Al-
though RNAi technology is available in some vertebrates
including the mouse, it is rarely used due to the length ofRNAi generation times and the lack of simplicity com-
pared with invertebrates [58].
Suitability of non-murine model organisms to study
22q11.2DS
Useful and valid model organisms should demonstrate ex-
amples of convergence with the human 22q11.2DS pheno-
type, thus providing proof-of-principle of the utility of
these organisms in characterizing gene function and dis-
ease modeling (e.g., as we observed here for TBX1). Cellu-
lar and phenotypic observations already made in lower
animals could identify new avenues of investigation regard-
ing the roles of particular genes in different 22q11.2DS
phenotypes. The limited data available make it difficult at
present to make phenotypic comparisons between species
that could help to indicate conserved molecular functions
of 22q11.2 genes, especially as such data were rarely col-
lected in the context of 22q11.2DS (Table 2). However the
data reveal opportunities for novel functional studies of
these genes.
One example of particular relevance to neurodevelop-
mental processes comes from PRODH, which encodes a
mitochondrial enzyme that metabolizes L-proline [63], an
amino acid involved in modulating glutamatergic and
GABA-ergic transmission [64]. A report of severe psycho-
motor delay in a male with a homozygous deletion [65] in-
dicates PRODH may also be an important candidate gene
for motor functioning. Movement abnormalities are com-
monly observed in individuals with 22q11.2DS, including
hypotonia in infancy, delayed gross-motor milestones in
childhood [66], susceptibility to antipsychotic-induced
movement disorders [67], and early-onset Parkinson’s dis-
ease [13], but it remains unclear which of the 22q11.2
genes are involved in these processes. Observations in the
fruit fly, however, suggest a novel role for PRODH in
motor pathways (Table 2). Its PRODH homologue, slgA, is
prominently expressed in the nervous system during em-
bryonic development and shows proline dehydrogenase
activity [63]. Fruit flies with a homozygous PRODH muta-
tion demonstrate severe locomotor defects and indecisive
movement patterns compared with wild-type flies in an
activity chamber assay [63]. Notably, this observation in
the fruit fly spurred the study of Prodh in locomotion in
mouse models, where the effects of Prodh have been less
clear [53, 54]. Further study on the role of PRODH in me-
diating 22q11.2DS associated motor deficits is warranted.
Gene knockout or knockdown technologies have only
recently been used in non-mouse model organisms, spe-
cifically in the context of 22q11.2DS phenotypes. One of
the few examples is SLC25A1, a mitochondrial citrate
transporter important for proper mitochondrial function-
ing. In zebrafish, knockdown of the SLC25A1 homologue,
slc25a1a, during embryonic development causes mito-
chondrial depletion and gross morphological defects that
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fish treated with a slc25a1a morpholino showed a dose-
dependent phenotype, with higher doses leading to more
severe developmental dysmorphic abnormalities such as a
flattened head and a marked reduction in the size of the
entire cranial region, including the brain [68]. Addition-
ally, fish with marked slc25a1a depletion had small hearts
surrounded by pericardial edema. These results indicate
that slc25a1a plays a role in cardiac as well as craniofacial
and brain development, all cardinal features of 22q11.2DS.
Notably, these phenotypes were rescued in treated animals
when autophagy was blocked [68]. SLC25A1 exemplifies
the potential for studies using knockdown models of sim-
pler organisms to investigate the molecular underpinning
of 22q11.2DS phenotypes that may yield novel therapeutic
targets.
A novel avenue of investigation based on the high de-
gree of gene conservation of mitochondrial genes in the
22q11.2DS region is also now indicated. Mitochondrial
dysfunction is implicated in the etiology of brain-based
disorders associated with 22q11.2DS, including develop-
mental delay, schizophrenia, and Parkinson’s disease
[69–71], and perturbation of mitochondria and related
pathways affects key cellular processes such as cell mi-
gration, apoptosis, and synapse formation [72]. Aberrant
expression of mitochondrial genes, already documented
in 22q11.2DS patients for five of the six (PRODH re-
mains unexamined) 22q11.2 mitochondrial genes [73],
all found in the human brain (Fig. 1), could mediate sus-
ceptibility to neurological conditions in individuals with
22q11.2DS. For example, MRPL40 knockouts in the fruit
fly show defects in neurogenesis that compromise neu-
rodevelopment (Table 2), and knockdowns of TXNRD2
in worms overexpressing human beta-amyloid peptide as
a model for Alzheimer’s disease were more susceptible
to muscular dysfunction and paralysis [74]. More com-
prehensive studies of neurodevelopment and neurode-
generation in lower organisms could shed light on the
molecular function of these critical proteins.
Individual organism suitability for studying specific
22q11.2DS phenotypes
Like the mouse [34, 35], zebrafish, fruit fly, and worm
models are unable to singularly recapitulate all of the
22q11.2DS associated phenotypes. A limitation for all
animal models is the challenge presented by complex
disease phenotypes, such as the range of psychiatric dis-
orders associated with 22q11.2DS. Particularly for simple
organisms, limited behaviors, and the paucity of repro-
ducible tests make it difficult to study such phenotypes.
Although a considerable number of genes are conserved
in the zebrafish, fruit fly, and worm, incomplete conser-
vation limits the ability to fully investigate the roles and
possible interactions between all 22q11.2 region genes.However, these issues should not discourage the further
study of specific 22q11.2DS orthologs. As discussed
below for each proposed model organism, orthologs in
lower animals could be very useful for clarifying the
roles of 22q11.2 deletion region genes in basic neurode-
velopmental trajectories (e.g. development of neuronal
components), as well as organ development. For ex-
ample, despite the absence of a heart in the worm, mu-
tants of mls-1 (the ortholog of TBX1) indicate that mls-1
is involved in the specification of non-striated muscle
during development [75], suggesting the potential utility
for these mutants in studying how TBX1 mediates heart
development in higher organisms. Discretion is essential
when deciding which model organism to use to study
particular 22q11.2DS phenotypes. However, organism-
specific characteristics and developmental trajectories do
suggest that certain 22q11.2DS phenotypes are particu-
larly well suited for study in each of these non-mouse
models.
Congenital cardiac defects, involving cardiovascular
molecular development, are major manifestations of
22q11.2DS [3] where the molecular underpinnings are dif-
ficult to analyze in mammalian models, since there is
rapid death without an intact cardiovascular system dur-
ing embryonic development [76]. Improvements in gener-
ating conditional gene deletion models using technologies
such as the Cre-loxP and Tet-On/Tet-Off system in mice
offer the potential to circumvent these issues, but have
not been fully developed in the context of investigating
congenital heart defects [77, 78]. Recently, the zebrafish
has emerged as a highly advantageous vertebrate model
for studying early cardiovascular development, largely due
to the ability of the zebrafish embryos to obtain oxygen in
the absence of blood circulation through passive diffusion.
1This permits survival of the initial stages of embryonic
development and allows investigation of even severe car-
diovascular defects [79]. The additional optical transpar-
ency of zebrafish embryos, used in combination with
tissue-specific expression of fluorescent proteins, permits
visualization of early molecular processes [80]. In humans,
TBX1 is associated with heart defects, palatal anomalies,
facial dysmorphism, and low calcium levels [81, 82] albeit
each with reduced penetrance [3]. In the zebrafish, inhibit-
ing the TBX1 homologue leads to developmental defects
of the pharyngeal arches, aortic arches, and thymus
(Table 2). Abnormal cardiac morphology was visible in
roughly 20 % of knockdowns, with compromised cardiac
performance in nearly all injected embryos [83]. The zeb-
rafish provides a unique opportunity to study early devel-
opment and how 22q11.2 gene dosage affects these
processes through the use of knockdown technologies.
The fruit fly is particularly well-suited for the study of the
myriad brain-related disorders associated with 22q11.2DS
[3, 6, 9, 13, 84], including intellectual disability, and other
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ders [86]. The benefits of using D. melanogaster include
its short generation time along with a high reproductive
rate and the availability of powerful genetic and mo-
lecular tools. Genes of interest can be readily manipu-
lated in a time and cell-or tissue-specific manner using
well-established tools such as the GAL4/UAS-system
[86]. Together with well-characterized developmental
stages, a simple and defined nervous system, and the
ability to conduct large-scale behavioral and neuro-
physiological assays, the fruit fly has proven a valuable
tool in the study of genomic and neurological disorders
[87]. Similar opportunities for study are possible for
22q11.2DS, although there have been few studies to date
targeted to 22q11.2DS (Table 2). Nevertheless, studies in
the fruit fly have already provided some novel insights into
the molecular function of 22q11.2 deletion region genes
pertinent to the associated neurological conditions. For
example, in the context of identifying novel intellectual
disability candidate genes in a large-scale screening study,
flies with a knockdown of SNAP29 were found to have
profound synaptic defects characterized by abnormal basal
neurotransmission [88] (Table 2).
To better assess the role of 22q11.2DS genes in devel-
opmental processes, additional molecular information is
needed, such as where and when a gene is expressed, and
elucidation of its protein-protein interactions. An ideal
model for these experiments is the worm. In addition to
having conserved fundamental biological processes and
homology with mammals, the worm is noteworthy for be-
ing highly amenable to forward and reverse genetic
screens [89, 90]. One 22q11.2DS gene provides an ex-
ample of the utility of using the worm system to study
22q11.2DS is DGCR8, a component of the “microproces-
sor” complex essential for genome-wide miRNA produc-
tion [91] that may mediate the expression of multiple
22q11.2DS associated phenotypes in patients, including
schizophrenia [41–43]. In mice, Dgcr8 has been implicated
in altering the biogenesis of genome-wide brain miRNA
[92]. Indeed, miRNAs were first discovered in 1993 in
genetic screens performed in the worm and were initially
thought to be phenomena unique to nematode biology
[93, 94]. It was later found that miRNA are widely con-
served among eukaryotes as functional non-coding RNAs
[95] and their role has been further studied in the mouse
[96], zebrafish [97], and fruit fly [98].
DGCR8 was first identified as a candidate gene for
miRNA processing based on a genome-wide two-hybrid
analysis of D. melanogaster where the protein product,
Pasha, was shown to interact with Drosha [99, 100]. In-
activation of a temperature sensitive allele of DGCR8 in
C. elegans lead to the accumulation of protein products of
other genes elsewhere in the genome, particularly let-7,
and a reduction in life span [101]. Similar mechanismscould be associated with the unexplained premature mortal-
ity reported in individuals with 22q11.2 DS [102]. In another
study investigating gene-gene interaction mechanisms,
RNAi targeting the worm DGCR8 homologue resulted
in exacerbation of the uncoordinated motor phenotype
caused either by a mutation in the human tau-FTDP-17
homologue or by unc (uncoordinated) mutations [103].
This is of interest in light of motor defects seen in patients
with 22q11.2DS [104, 105]. Comparable interactive mech-
anisms, involving effects of hemizygosity of DGCR8 on
expression of mRNA across the genome, may also be op-
erating in 22q11.2DS [41–43]. Differences in mRNA ex-
pression may also be mediated by another 22q11.2 region
gene, DGCR14, whose ortholog in C. elegans has been im-
plicated in promoting proper mRNA splicing when splice
sites are compromised [106]. Notably, conservation is a
key means of determining relevance of a non-protein-
coding sequence in humans [107].
Another as yet unexplored area in the context of model
organisms and 22q11.2DS relates to the development of
pharmaceutical agents to treat 22q11.2DS related pheno-
types. Collectively, D. rerio, D. melanogaster, and C. ele-
gans are particularly suited to screening chemical libraries
for potential drug development, circumventing the high fi-
nancial and time investment for M. musculus [108].
Study limitations
We used a reciprocal best hits method to identify puta-
tive orthologs of human 22q11.2 genes in simple model
organisms, a common and well-established method to
probe orthology based on sequence similarity [39]. In
this exploratory study, we did not restrict to a minimum
sequence identity in order to identify all putative ortho-
logs of the human 22q11.2 genes. Similarity in protein
sequences does not necessarily translate to conserved
function or patterns of gene expression across species.
Further experiments are needed to assay possible con-
served functional roles [109, 110] of the homologues iden-
tified here. Importantly, we found that our results were
consistent with previous homology relationships described
for 22q11.2DS genes (e.g., PRODH [111], UFD1L [112],
DGCR6 [113], MED15 [114], TSSK2 [115], and TXNRD2
[116]). Using these methods, we identified multiple puta-
tive homologues for individual 22q11.2 deletion region
genes in the zebrafish, possibly related to gene duplication
[45]. In these cases, functional studies are required to
examine which homologue may have a conserved function.
Additionally, using the stringent criteria for the reciprocal
best hits method, homology may be difficult to establish
for genetically distant species. For example, query coverage
was too low to identify a reciprocal best hit for the mito-
chondrial gene ZDHHC8 in the fruit fly and worm. Our
analyses were restricted to protein-coding genes and miR-
NAs. The examination of other non-coding genes will be
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For the 17 genes conserved across all species examined, we
noted some discrepancies in mutant phenotypes across
species that could suggest divergent gene functions
(Table 2). However, this is likely related to the absence of
studies of comparable phenotypes (e.g., the cardiovascular
system investigated in one organism but not another) and
the relative sparseness of available data for many genes.
Conclusions
These results indicate that the zebrafish, fruit fly, and
worm are valuable but underused model organisms in
the study of the important human genetic syndrome,
22q11.2DS, associated with a 22q11.2 deletion involving
46 protein-coding genes. There is a relatively high de-
gree of conservation of these genes, and some relevant
models already exist in non-murine organisms. Despite
this, few have been studied in the context of 22q11.2DS.
Manipulating expression of 22q11.2 region genes in the
zebrafish, fruit fly, or worm can reveal phenotypic mani-
festations relevant to 22q11.2DS and a greater under-
standing of their molecular origins in ways that are not
possible in humans or readily possible in mouse models.
In addition to providing a novel comprehensive com-
parative resource for the many developmental genes in
the 22q11.2 region, we illustrate a proof-of-principle of
the utility for applying a similar approach to investigat-
ing other pathogenic copy number variants associated
with multi-system developmental disorders and import-
ant neurodevelopmental phenotypes.
Additional file
Additional file 1: 22q11.2 gene homologue locations. The human
22q11.2DS deletion region genetic content and order was mapped from
NCBI Gene Homo sapiens Annotation Release 105 using Affymetrix CytoScan
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ascertained from 16 patients with confirmed 22q11.2 deletions. Protein Basic
Local Alignment Search Tool (blastp) analysis on UniProtKB was used to identify
putative homologues using the reciprocal best-hits method. NCBI was used
to find gene coordinates of putative homologues. All data were recent to
2 December 2014. See Methods for additional details.
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